Free Trial
→ This free guide explains options the way they should be taught (From Base Camp Trading) (Ad)tc pixel
NASDAQ:ACIU

AC Immune Q3 2026 Earnings Date & Estimates

AC Immune logo
$2.50 -0.05 (-1.96%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.50 0.00 (0.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AC Immune is expected to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for November 4, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from AC Immune in Q3 2026

AC Immune is expected to post earnings of -$0.22 per share on revenue of $0.33 million. In the same quarter a year earlier AC Immune reported -$0.20 per share on revenue of $1.18 million. AC Immune last reported on August 6, 2026, posting $0.03 per share and beating the -$0.1044 consensus estimate. AC Immune has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.22
Expected Revenue
$0.33 million
Prior-Year EPS
-$0.20
Prior-Year Revenue
$1.18 million
Expected Revenue Growth
-72.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.03 (Beat by +$0.1344)
Last Quarter Revenue
$18.67 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

AC Immune Q3 2026 Earnings FAQ

AC Immune (NASDAQ:ACIU) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

AC Immune's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect AC Immune to post earnings of -$0.22 per share for Q3 2026.

The consensus revenue estimate for AC Immune is $0.33 million for Q3 2026.

AC Immune Earnings Headlines

AC Immune (NASDAQ:ACIU) Stock Has Consensus Target Price of $7.50 According to Brokerages
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090256
AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting
October 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ac-immune-adds-tom-graney-to-board-following-extraordinary-general-meeting?utm_source=marketbeat.com&utm_medium=referral
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.tc pixel
 |  Stansberry Research (Ad)
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
September 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949555-ac-immune-buy-continued-aci-7104-progress-pd-and-pipeline-expansions?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
AC Immune Reports Positive Safety and Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
September 24, 2026  |  marketscreener.comM
Fein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target Maintained
September 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/fein-reiterates-buy-on-ac-immune-as-vacsyn-phase-2-data-validate-platform-12-price-target-maintained-ratings-news?utm_source=marketbeat.com&utm_medium=referral
See More AC Immune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email.

About AC Immune

AC Immune (NASDAQ:ACIU) SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. The company develops precision medicines and diagnostic products for neurodegenerative diseases, with a primary focus on Alzheimer’s disease and other conditions involving the abnormal accumulation or misfolding of proteins in the brain.

AC Immune’s research platform includes SupraAntigen, which is designed to generate antibodies against pathological forms of proteins, and Morphomer, a technology focused on identifying small molecules that can target and potentially prevent protein misfolding. Its pipeline has included investigational vaccines, antibodies and small-molecule therapies directed at amyloid-beta, tau and other disease-associated proteins.

Founded in 2003, AC Immune conducts research and clinical development through international collaborations and partnerships. Its programs have been evaluated in clinical studies across multiple geographies, including North America and Europe. The company is led by Chief Executive Officer Andrea Pfeifer, who has guided its development as a neuroscience-focused biotechnology company.

View AC Immune Profile
Earnings Tools